Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Cencora Earnings Call: Key Takeaways

Cencora delivered strong FY2026 results with 14% operating income growth and introduced a new reporting structure to highlight high-growth specialty services and MSO platforms.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthUS Healthcare up 5% to $78.3B; International up 5% to $7.8B.
Mgmt ConfidenceHigh confidence in long-term targets and new pharmaceutical-centric operating model.
Demand VisibilityExpect specialty distribution revenue to reach approximately $100 billion in FY2027.
Margin TrendsAdjusted gross margin expanded 57 basis points to 4.04% in Q4.
Op. LeverageOperating expenses grew 23% primarily due to OneOncology acquisition impact.
Pricing PowerManufacturer list price reductions created a $2.8 billion headwind to revenue.
Vol vs PriceGrowth driven by specialty volume strength and GLP-1 demand ($2.8B increase).
Segment GrowthSpecialty segment long-term operating income growth targeted at mid-teens percentage.
New ClientsAcquired OneOncology; majority interest agreement in American Oncology Network (AON).
Capex & DebtFY2027 CAPEX $1B; $1.25B share repurchases; $1B debt repayment planned.
RegulatoryMonitoring IRA impacts and potential policy changes following the recent election.
CommentaryStrategic pivot to a pharmaceutical-centric model focusing on high-margin specialty services.
New LaunchesIntroduced AI-powered tools for independent pharmacies at ThoughtSpot trade show.

Growth

FY2026 revenue grew 5% to $337B; adjusted diluted EPS rose 12% to $17.97.

Outlook

FY2027 EPS guided to $19.40-$19.75; specialty segment operating income growth expected at 18-21%.

Risks

Management used vague language regarding the specific financial impact of losing the Option Care contract.

Source

The company's earnings call, NYSE: COR, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Cencora, Inc.: key numbers

Share price
$356.94Close, Nov 16
Market cap
$68.1B
Shares outstanding
190.83MLatest SEC cover page
Sector
Trade & Services
Industry
Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cencora, Inc.

All →
9:26 AM ET 8-K
Business Update

Cencora Business Update

Cencora, Inc. announced a reorganization of its operating model and reporting structure to advance growth priorities and improve visibility. Beginning in fiscal 2027, the company will report results across three segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The filing includes supplemental unaudited historical segment data for fiscal 2025 and 2026 recast under this new structure to assist investor analysis.

6:38 AM ET 8-K
Financial Results

Cencora Financial Results

Cencora reported fiscal year 2026 revenue of $337.4 billion, up 5.0% year-over-year, and adjusted diluted EPS of $17.97. The company introduced a new operating model and reportable segments following its acquisition of OneOncology and provided fiscal 2027 adjusted EPS guidance of $19.40 to $19.75.

Term
FY2026

“Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results.”

Robert P. Mauch, President and Chief Executive Officer of Cencora

“As we enter fiscal 2027, our new operating model is designed to strengthen our execution and provide visibility to our progress.”

Robert P. Mauch, President and Chief Executive Officer of Cencora
4:07 PM ET Form 4
Insider Selling

Cencora SVP & CAO Lazarus Krikorian Sells $326K of Stock

Lazarus Krikorian, SVP & CAO, sold 986 shares of Cencora, Inc. at $330.96 a share, worth $326K in total on Nov 2, 2026. Shares held after the trade: 14,197 (-6.5%).

Value
$326K
Shares
986
Price
$330.96
Role
SVP & CAO
Holding change
-6.5%
Trade date
Nov 2, 2026
7:49 AM ET 8-K
M&A Deal

Cencora Signs $2.4B M&A Deal with American Oncology Network, Inc.

Cencora has signed a definitive agreement to acquire American Oncology Network (AON) for an enterprise value of $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The acquisition expands Cencora's oncology management services organization (MSO) platform by adding a network of over 350 oncology providers across 21 states.

Value
$2.4B
Counterparty
American Oncology Network, Inc.
3:59 PM ET Form 4
Insider Selling

Cencora SVP & CAO Lazarus Krikorian Sells $299K of Stock

Lazarus Krikorian, SVP & CAO, sold 986 shares of Cencora, Inc. at $303.18 a share, worth $299K in total on Oct 1, 2026. Shares held after the trade: 15,183 (-6.1%).

Value
$299K
Shares
986
Price
$303.18
Role
SVP & CAO
Holding change
-6.1%
Trade date
Oct 1, 2026
8:11 AM ET 8-K
Leadership Change

Cencora Leadership Change

Cencora, Inc. appointed Robert E. Sanchez, the former Executive Chair and CEO of Ryder System, Inc., to its Board of Directors effective October 1, 2026. In connection with the appointment, the Board increased its size from ten to eleven members. Mr. Sanchez will receive standard non-employee director compensation, including a pro-rated annual equity award.

Counterparty
Robert E. Sanchez

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.